Aurisco Pharmaceutical Co Ltd (605116) - Total Liabilities

Latest as of June 2025: CN¥1.47 Billion CNY ≈ $215.58 Million USD

Based on the latest financial reports, Aurisco Pharmaceutical Co Ltd (605116) has total liabilities worth CN¥1.47 Billion CNY (≈ $215.58 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Aurisco Pharmaceutical Co Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how Aurisco Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Aurisco Pharmaceutical Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Aurisco Pharmaceutical Co Ltd Competitors by Total Liabilities

The table below lists competitors of Aurisco Pharmaceutical Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Red Star Macalline Group Corp Ltd Class A SHG:601828	China	CN¥67.39 Billion
Jutze Intelligent Technology Co Ltd SHE:300802	China	CN¥391.11 Million
TTW Public Company Limited BK:TTW	Thailand	฿6.82 Billion
Chengdu Easton Biopharmaceuticals Co Ltd SHG:688513	China	CN¥691.49 Million
Pennant Group Inc NASDAQ:PNTG	USA	$567.05 Million
Reit 1 TA:RIT1	Israel	ILA4.85 Billion
Corbion NV AS:CRBN	Netherlands	€674.30 Million
Avanos Medical Inc NYSE:AVNS	USA	$268.00 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Aurisco Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 605116 company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	4.51	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.61	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.38	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Aurisco Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Aurisco Pharmaceutical Co Ltd (2016–2024)

The table below shows the annual total liabilities of Aurisco Pharmaceutical Co Ltd from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥1.55 Billion ≈ $226.21 Million	+154.67%
2023-12-31	CN¥607.03 Million ≈ $88.83 Million	+74.09%
2022-12-31	CN¥348.68 Million ≈ $51.02 Million	+63.37%
2021-12-31	CN¥213.44 Million ≈ $31.23 Million	+44.23%
2020-12-31	CN¥147.98 Million ≈ $21.65 Million	+20.34%
2019-12-31	CN¥122.96 Million ≈ $17.99 Million	-7.65%
2018-12-31	CN¥133.16 Million ≈ $19.48 Million	+0.54%
2017-12-31	CN¥132.44 Million ≈ $19.38 Million	-31.03%
2016-12-31	CN¥192.01 Million ≈ $28.10 Million	--

About Aurisco Pharmaceutical Co Ltd

SHG:605116 China Biotechnology

Market Cap

$1.16 Billion

CN¥7.95 Billion CNY

Market Cap Rank

#8408 Global

#2064 in China

Share Price

CN¥19.56

Change (1 day)

+0.77%

52-Week Range

CN¥18.37 - CN¥34.43

All Time High

CN¥34.43